Skip to main content
Top
Published in: International Journal of Hematology 3/2016

01-09-2016 | Rapid Communication

Transition of adult T-cell leukemia/lymphoma clones during clinical progression

Authors: Sakura Aoki, Sanaz Firouzi, Yosvany López, Tadanori Yamochi, Kazumi Nakano, Kaoru Uchimaru, Atae Utusnomiya, Masako Iwanaga, Toshiki Watanabe

Published in: International Journal of Hematology | Issue 3/2016

Login to get access

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell neoplasm caused by the transformation of HTLV-1-infected T cells. ATLL, especially its aggressive form, is known for its poor prognosis, even with intensive chemotherapy. ATLL cells are considered to be monoclonal; however, multiclonal proliferation or emergence of a new clone over time has been reported based on Southern blot analysis, although direct molecular evidence remains elusive. Furthermore, it is thought that clonal change may be a cause of early drug resistance in ATLL. To directly analyze potential clonal changes in ATLL during its clinical course, we used inverse PCR to detect integration sites in combination with a newly developed method using next-generation sequencing, and compared ATLL cell clonality at different time points. The results of inverse PCR indicated that the major clone was altered in three of 19 patients. Together with results from five patients, using this new method, we found direct evidence of clonal change occurring during the clinical course or in response to chemotherapy in ATLL. These results also highlight the importance of clonality analysis for understanding the mechanisms of ATLL development and drug resistance.
Literature
2.
go back to reference Yasunaga J, Matsuoka M. Molecular mechanisms of HTLV-1 infection and pathogenesis. Int J Hematol. 2011;94:435–42.CrossRefPubMed Yasunaga J, Matsuoka M. Molecular mechanisms of HTLV-1 infection and pathogenesis. Int J Hematol. 2011;94:435–42.CrossRefPubMed
3.
go back to reference Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-1 associated myelopathy, a new clinical entity. Lancet. 1986;1:1031–2.CrossRefPubMed Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-1 associated myelopathy, a new clinical entity. Lancet. 1986;1:1031–2.CrossRefPubMed
4.
go back to reference Mochizuki M, Watanabe T, Yamaguchi K, Takatsuki K, Yoshimura K, Shirao M, et al. HTLV-1 uveitis: a distinct clinical entity caused by HTLV-1. Jpn J Cancer Res. 1992;83:236–9.CrossRefPubMed Mochizuki M, Watanabe T, Yamaguchi K, Takatsuki K, Yoshimura K, Shirao M, et al. HTLV-1 uveitis: a distinct clinical entity caused by HTLV-1. Jpn J Cancer Res. 1992;83:236–9.CrossRefPubMed
5.
go back to reference Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA. 1984;81:2534–7.CrossRefPubMedPubMedCentral Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA. 1984;81:2534–7.CrossRefPubMedPubMedCentral
6.
go back to reference Kamihira S, Sugahara K, Tsuruda K, Minami S, Uemura A, Akamatsu N, et al. Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells. Clin Lab Haematol. 2005;27:235–41.CrossRefPubMed Kamihira S, Sugahara K, Tsuruda K, Minami S, Uemura A, Akamatsu N, et al. Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells. Clin Lab Haematol. 2005;27:235–41.CrossRefPubMed
7.
go back to reference Cavrois M, Gessain A, Wain-Hobson S, Wattel E. Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Oncogene. 1996;12:2419–23.PubMed Cavrois M, Gessain A, Wain-Hobson S, Wattel E. Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Oncogene. 1996;12:2419–23.PubMed
8.
go back to reference Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, et al. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Res. 1997;57:4862–7.PubMed Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, et al. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Res. 1997;57:4862–7.PubMed
9.
go back to reference Gillet NA, Malani N, Melamed A, Gormley N, Carter R, Bentley D, et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood. 2011;117:3113–22.CrossRefPubMedPubMedCentral Gillet NA, Malani N, Melamed A, Gormley N, Carter R, Bentley D, et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood. 2011;117:3113–22.CrossRefPubMedPubMedCentral
10.
go back to reference Firouzi S, López Y, Suzuki Y, Nakai K, Sugano S, Yamochi T, et al. Development and validation of a new high-throughput method to investigate the clonality of HTLV-1-infected cells based on provirus integration sites. Genome Med. 2014;6:46.CrossRefPubMedPubMedCentral Firouzi S, López Y, Suzuki Y, Nakai K, Sugano S, Yamochi T, et al. Development and validation of a new high-throughput method to investigate the clonality of HTLV-1-infected cells based on provirus integration sites. Genome Med. 2014;6:46.CrossRefPubMedPubMedCentral
11.
go back to reference Tanaka G, Okayama A, Watanabe T, Aizawa S, Stuver S, Mueller N, et al. The clonal expansion of human T lymphotropic virus type 1-infected T cells: a comparison between seroconverters and long-term carriers. J Infect Dis. 2005;191:1140–7.CrossRefPubMed Tanaka G, Okayama A, Watanabe T, Aizawa S, Stuver S, Mueller N, et al. The clonal expansion of human T lymphotropic virus type 1-infected T cells: a comparison between seroconverters and long-term carriers. J Infect Dis. 2005;191:1140–7.CrossRefPubMed
12.
go back to reference Kamihira S, Iwanaga M, Doi Y, Sasaki D, Mori S, Tsurda K, Nagai K, et al. Heterogeneity in clonal nature in the smoldering subtype of adult T-cell leukemia: continuity from carrier status to smoldering ATL. Int J Hematol. 2012;95:399–408.CrossRefPubMed Kamihira S, Iwanaga M, Doi Y, Sasaki D, Mori S, Tsurda K, Nagai K, et al. Heterogeneity in clonal nature in the smoldering subtype of adult T-cell leukemia: continuity from carrier status to smoldering ATL. Int J Hematol. 2012;95:399–408.CrossRefPubMed
13.
go back to reference Shimamoto Y, Kikuchi M, Funai N, Suga K, Matsuzaki M, Yamaguchi M. Spontaneous remission in adult T-cell leukemia/lymphoma. Cancer. 1993;72:735–40.CrossRefPubMed Shimamoto Y, Kikuchi M, Funai N, Suga K, Matsuzaki M, Yamaguchi M. Spontaneous remission in adult T-cell leukemia/lymphoma. Cancer. 1993;72:735–40.CrossRefPubMed
14.
go back to reference Tsukasaki K, Tsushima H, Yamamura M, Hata T, Murata K, Maeda T, et al. Integration patterns of HTLV-1 provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood. 1997;89:948–56.PubMed Tsukasaki K, Tsushima H, Yamamura M, Hata T, Murata K, Maeda T, et al. Integration patterns of HTLV-1 provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood. 1997;89:948–56.PubMed
15.
go back to reference Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh K-R, et al. Development (JSPFAD) investigators. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211–9.CrossRefPubMed Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh K-R, et al. Development (JSPFAD) investigators. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211–9.CrossRefPubMed
16.
go back to reference Kuramitsu M, Okuma K, Yamochi T, Sato T, Sasaki S, Hasegawa H, Umeki K, et al. Standardization of quantitative PCR for human T-cell leukemia virus type 1 in Japan: a collaborative Study. J Clin Microbiol. 2015;53:3485–91.CrossRefPubMedPubMedCentral Kuramitsu M, Okuma K, Yamochi T, Sato T, Sasaki S, Hasegawa H, Umeki K, et al. Standardization of quantitative PCR for human T-cell leukemia virus type 1 in Japan: a collaborative Study. J Clin Microbiol. 2015;53:3485–91.CrossRefPubMedPubMedCentral
17.
go back to reference Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.CrossRefPubMedPubMedCentral Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.CrossRefPubMedPubMedCentral
18.
go back to reference Stasinopoulos DM, Rigby RA. Generalized additive models for location scale and shape (GAMLSS) in R. J Stat Softw. 2007;23:1–46.CrossRef Stasinopoulos DM, Rigby RA. Generalized additive models for location scale and shape (GAMLSS) in R. J Stat Softw. 2007;23:1–46.CrossRef
Metadata
Title
Transition of adult T-cell leukemia/lymphoma clones during clinical progression
Authors
Sakura Aoki
Sanaz Firouzi
Yosvany López
Tadanori Yamochi
Kazumi Nakano
Kaoru Uchimaru
Atae Utusnomiya
Masako Iwanaga
Toshiki Watanabe
Publication date
01-09-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2049-4

Other articles of this Issue 3/2016

International Journal of Hematology 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine